CollPlant Biotechnologies (CLGN) Competitors

CollPlant Biotechnologies (NASDAQ:CLGN) and BrainsWay (NASDAQ:BWAY) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, community ranking, risk, media sentiment and profitability.

Which has preferable valuation and earnings, CLGN or BWAY?

BrainsWay has higher revenue and earnings than CollPlant Biotechnologies. CollPlant Biotechnologies is trading at a lower price-to-earnings ratio than BrainsWay, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CollPlant Biotechnologies	$10.96M	4.21	-$7.02M	-$1.54	-2.62
BrainsWay	$31.78M	6.05	-$4.20M	$0.10	102.31

Which has more volatility and risk, CLGN or BWAY?

CollPlant Biotechnologies has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500. Comparatively, BrainsWay has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500.

Does the MarketBeat Community believe in CLGN or BWAY?

CollPlant Biotechnologies received 69 more outperform votes than BrainsWay when rated by MarketBeat users. However, 66.99% of users gave BrainsWay an outperform vote while only 59.48% of users gave CollPlant Biotechnologies an outperform vote.

Company	Underperform	Outperform
CollPlant Biotechnologies	Outperform Votes 138 59.48%	Underperform Votes 94 40.52%
BrainsWay	Outperform Votes 69 66.99%	Underperform Votes 34 33.01%

Do analysts rate CLGN or BWAY?

CollPlant Biotechnologies currently has a consensus target price of $12.50, indicating a potential upside of 210.17%. BrainsWay has a consensus target price of $13.17, indicating a potential upside of 28.71%. Given CollPlant Biotechnologies' stronger consensus rating and higher possible upside, analysts clearly believe CollPlant Biotechnologies is more favorable than BrainsWay.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CollPlant Biotechnologies	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33
BrainsWay	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media prefer CLGN or BWAY?

In the previous week, BrainsWay had 1 more articles in the media than CollPlant Biotechnologies. MarketBeat recorded 1 mentions for BrainsWay and 0 mentions for CollPlant Biotechnologies. BrainsWay's average media sentiment score of 0.82 beat CollPlant Biotechnologies' score of -1.00 indicating that BrainsWay is being referred to more favorably in the news media.

Company	Overall Sentiment
CollPlant Biotechnologies	Negative
BrainsWay	Positive

Do insiders & institutionals have more ownership in CLGN or BWAY?

21.7% of CollPlant Biotechnologies shares are held by institutional investors. Comparatively, 30.1% of BrainsWay shares are held by institutional investors. 9.6% of CollPlant Biotechnologies shares are held by insiders. Comparatively, 19.0% of BrainsWay shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Is CLGN or BWAY more profitable?

BrainsWay has a net margin of 3.88% compared to CollPlant Biotechnologies' net margin of -2,680.00%. BrainsWay's return on equity of 3.52% beat CollPlant Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CollPlant Biotechnologies	-2,680.00%	-77.05%	-61.43%
BrainsWay	3.88%	3.52%	2.26%

Summary

BrainsWay beats CollPlant Biotechnologies on 15 of the 19 factors compared between the two stocks.